The U.S. Food and Drug Administration (FDA) has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating disorder (BED) in adults. Lisdexamfetamine is the only approved treatment for binge eating disorder. Although restricted as a Schedule II controlled substance like other stimulants, as a prodrug lisdexamfetamine may have less propensity for abuse, intoxication, or dependence than other stimulants. Lisdexamfetamine may be particularly useful in adult patients without prior diagnosis and treatment of ADHD as a child to prevent abuse and diversion since lisdexamfetamine may be less abusable than other stimulants. FDA-approved generic medicines work in the same way and provide the same clinical benefit and risks as their brand-name counterparts.

>>  FDA News Release